मुख्यपृष्ठ › मल्टिपल मायलोमा › टेक्सास › Dallas
Dallas, TX मधील मल्टिपल मायलोमा साठी क्लिनिकल ट्रायल्स
Dallas आणि आजूबाजूच्या ठिकाणी (सुमारे 30 मैलांच्या आत) मल्टिपल मायलोमा साठी 17 अभ्यास सहभागी शोधत आहेत. कोण सहभागी होऊ शकते आणि अभ्यास संघाशी संपर्क कसा साधावा हे पाहण्यासाठी अभ्यास उघडा.
अधिकृत अभ्यास मजकूर (इंग्रजी)
अभ्यासासाठी सहभागी शोधत आहात? हे पृष्ठ शीर्षस्थानी दर्शवा — 30 दिवसांसाठी $99 →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
निवड सुरू आहेफेज 3
- Research Site, Dallas
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
निवड सुरू आहेफेज 3
- Baylor University Medical Center, Dallas
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
निवड सुरू आहेफेज 3
- Baylor University Medical Center, Dallas
- UT Southwestern Medical Center, Dallas
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
निवड सुरू आहेफेज 3
- University of Texas Southwestern Medical Center, Dallas
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
निवड सुरू आहेफेज 2
- UT Southwestern Medical Center, Dallas
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
निवड सुरू आहेफेज 1/2
- University of Texas - Southwestern Medical Center /ID# 271914, Dallas
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
निवड सुरू आहेफेज 3
- Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy, Dallas
- Baylor University Medical Center, Dallas
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
निवड सुरू आहेफेज 1
- University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
निवड सुरू आहेफेज 1/2
- Research Site, Dallas
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
निवड सुरू आहेफेज 3
- Research Site, Dallas
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
निवड सुरू आहेफेज 1
- Baylor University Medical Center, Dallas
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
निवड सुरू आहेफेज 1/2
- University of Texas - Southwestern Medical Center /ID# 274360, Dallas
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
निवड सुरू आहेफेज 1
- Texas Oncology - Dallas - Worth Street /ID# 280064, Dallas
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
निवड सुरू आहेफेज 1
- University of Texas Southwestern, Dallas
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
निवड सुरू आहेफेज 2
- University of Texas Southwestern, Dallas
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
निवड सुरू आहेनिरीक्षण अभ्यास
- Ut Southwestern, Dallas
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
निवड सुरू आहेफेज 1
- University of Texas Southwestern Medical Center, Dallas
इतर शहरांतील मल्टिपल मायलोमा ट्रायल्स
- New York City, NY60 अभ्यास
- Boston, MA42 अभ्यास
- Atlanta, GA41 अभ्यास
- Houston, TX38 अभ्यास
- Durham, NC37 अभ्यास
- Nashville, TN32 अभ्यास
- Denver, CO27 अभ्यास
- Rochester, MN24 अभ्यास
- St. Louis, MO24 अभ्यास
- Columbus, OH24 अभ्यास
- Baldwin Park, CA23 अभ्यास
- Chicago, IL22 अभ्यास
Dallas मधील इतर अभ्यास
- स्तनाचा कर्करोग55 अभ्यास
- नॉन-स्मॉल सेल लंग कॅन्सर52 अभ्यास
- मेटास्टॅटिक कर्करोग42 अभ्यास
- हृदयाची अशक्तपणा42 अभ्यास
- कर्करोग (सर्व प्रकार)37 अभ्यास
- प्रोस्टेट कर्करोग36 अभ्यास
- कोलोरॅक्टल कॅन्सर33 अभ्यास
- स्थूलता30 अभ्यास
- अंडाशयाचा कर्करोग28 अभ्यास
- मूत्राशय कर्करोग27 अभ्यास
- फुफ्फुसाचा कॅन्सर27 अभ्यास
- एंडोमेट्रियल कर्करोग24 अभ्यास
ClinicalTrials.gov वरून, 5 ऑक्टो, 2026 रोजी मिळालेली माहिती. प्रत्येक अभ्यासासाठी पात्रतेचे निकष वेगळे असतात; अभ्यास संघ ठरवतो की कोण सहभागी होऊ शकते.